Literature DB >> 9230242

Community-acquired pneumonia: the annual cost to the National Health Service in the UK.

J F Guest1, A Morris.   

Abstract

The aim of this study was to estimate the direct annual healthcare costs to the UK National Health Service (NHS) of managing community-acquired pneumonia. Using a prevalence-based burden of illness approach, health service resource use and corresponding costs attributable to the management of community-acquired pneumonia during 1992/1993 in the UK were obtained from published sources and commercial databases, and supplemented by a telephone survey of general practitioners, finance directors, community nurses, receptionists and nurses in out-patient respiratory clinics, ambulance services, and consultant respiratory physicians. The study was appraised by a Peer Review Panel, representing a cross-section of experts from different locations. This study was a predefined subgroup analysis of a previous, larger study that estimated the annual cost to the NHS of treating all community-acquired lower respiratory tract infections. The analysis shows that there are 261,000 episodes of community-acquired pneumonia annually in the UK, costing 440.7 million pounds at 1992/1993 prices (32% of the annual cost for all community-acquired lower respiratory tract infections). Approximately 83,153 annual cases of community-acquired pneumonia are treated in hospital (32% of all episodes) and account for 96% of the annual cost. The average cost for managing pneumonia in the community is 100 pounds per episode, compared to 1,700-5,100 pounds when the patient is hospitalized, depending on the length of hospitalization. Hospitalization accounts for 87% of the total annual cost. In conclusion, community-acquired pneumonia in the UK incurs a direct healthcare cost of 440.7 million pounds annually at 1992/1993 prices. Developing and implementing strategies to prevent and minimize hospitalization will significantly reduce this annual cost and should be assessed in future studies.

Entities:  

Mesh:

Year:  1997        PMID: 9230242     DOI: 10.1183/09031936.97.10071530

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  46 in total

1.  Providing better care for patients who may have pneumonia.

Authors:  W F Holmes; M Woodhead
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.

Authors:  B G Feagan; T J Marrie; C Y Lau; S L Wheeler; C J Wong; M K Vandervoort
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

3.  Severity prediction rules in community acquired pneumonia: a validation study.

Authors:  W S Lim; S Lewis; J T Macfarlane
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

4.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 5.  Economic aspects of pneumococcal pneumonia: a review of the literature.

Authors:  Diana De Graeve; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 6.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

7.  Severe community acquired pneumonia.

Authors:  Graham D Mills; Richard Laing
Journal:  BMJ       Date:  2006-12-09

8.  Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis.

Authors:  Zoe Athanassa; Gregory Makris; George Dimopoulos; Matthew E Falagas
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  South African guideline for the management of community-acquired pneumonia in adults.

Authors:  Tom H Boyles; Adrian Brink; Greg L Calligaro; Cheryl Cohen; Keertan Dheda; Gary Maartens; Guy A Richards; Richard van Zyl Smit; Clifford Smith; Sean Wasserman; Andrew C Whitelaw; Charles Feldman
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

10.  Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.

Authors:  Konstantinos Z Vardakas; Ilias I Siempos; Alexandros Grammatikos; Zoe Athanassa; Ioanna P Korbila; Matthew E Falagas
Journal:  CMAJ       Date:  2008-12-02       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.